An update from NLS Pharmaceutics ( (NLSP) ) is now available.
On February 10, 2025, NLS Pharmaceutics Ltd. announced a strategic merger with Kadimastem Ltd., aimed at revolutionizing diabetes treatment through a multi-target approach. The merger seeks to integrate NLS’s pharmaceutical innovations with Kadimastem’s cell therapy expertise to address the multifaceted challenges of diabetes, including neurological and systemic complications. By introducing DOXA, a novel therapeutic platform, the companies aim to set a new standard in diabetes management, augmenting existing treatments with comprehensive solutions that enhance metabolic regulation and insulin sensitivity. This merger is anticipated to strengthen their position in the biotech industry and offer transformative solutions for patients and stakeholders.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and complex central nervous system disorders. The company is actively engaged in innovative pharmaceutical development, particularly targeting complex conditions that affect the nervous system.
YTD Price Performance: -14.22%
Average Trading Volume: 2,049,121
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.62M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.